On January 14, 2026, this newsletter featured 1 cluster buy and 5 insider purchases detected from SEC Form 4 filings.
📈 Daily Insider & Cluster Buy Highlights – January 14, 2026
Here are some of the most interesting insider and cluster buying signals from the last 7 days.
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 About Fair Value:
The Fair Value shown for each company is calculated using a Levered Discounted Cash Flow (DCF) model. This method estimates the intrinsic value of a stock by projecting future cash flows and discounting them back to present value, accounting for the company's debt structure. A positive percentage difference indicates the stock may be undervalued relative to this model, while a negative percentage suggests it may be overvalued. Fair value calculations are estimates and should be considered alongside other factors.
🔥 Notable Cluster Buys (≥ $500,000)
$71.41
Current Price
52W: Low: $68.98 | High: $79.65
Participants: 2 insiders
Total Shares: 24,500
Total Value: $1,730,980
Timeframe: 0 days
Date Range: Jan 09, 2026 to Jan 09, 2026
👥 Participant Details:
Coughenour Peter
Officer
Date: Jan 09, 2026
500 shares
$34,900
@ $69.80/share
P&L: +2.3% (+$805)
AGREE RICHARD
Director
Date: Jan 09, 2026
24,000 shares
$1,696,080
@ $70.67/share
P&L: +1.0% (+$17,760)
📈 Average P&L: +1.7% (+9,282)
Current Price: $71.41
📊 Valuation & Analyst Info:
Fair Value: $302.21 (323.2% undervalued vs current price)
Analyst Rating: B
Avg Price Target: $80.93 (+13.3% vs current)
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 13, 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are...
Business Wire • Jan 13, 2026
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividen...
Seeking Alpha • Jan 12, 2026
Dividend investing is increasingly vital amid higher rates and inflation, offering passive income and wealth compounding for retirement. Anchoring a portfolio with quality dividend ETFs like SCHD, FDV...
Business Wire • Jan 12, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab...
Seeking Alpha • Jan 10, 2026
REITs, after years of underperformance, are now attractively valued and poised for strong returns over the next 12–18 months. VICI Properties, NNN REIT, and Agree Realty offer robust yields, improving...
PRNewsWire • Jan 08, 2026
Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provi...
PRNewsWire • Jan 08, 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advise...
PRNewsWire • Jan 08, 2026
LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
Defense World • Jan 08, 2026
CoreCap Advisors LLC boosted its holdings in shares of Agree Realty Corporation (NYSE: ADC) by 15.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exch...
💼 Notable Individual Insider Buys (≥ $100,000)
Transaction Date: Jan 09, 2026
Shares: 588,235
Purchase Price: $17.00
Purchase Value: $9,999,995
📈
P&L: 30.1% ($3,005,881 gain)
📊 Valuation & Analyst Info:
Fair Value: $4.90 (77.8% overvalued vs current price)
Analyst Rating: C+
Avg Price Target: $35.14 (+58.9% vs current)
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 09, 2026
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
GlobeNewsWire • Jan 07, 2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Zacks Investment Research • Jan 07, 2026
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
Seeking Alpha • Jan 07, 2026
Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, wit...
Defense World • Jan 07, 2026
Alumis (NASDAQ: ALMS) used a conference call to highlight positive top-line Phase III results for envudeucitinib, its next-generation oral TYK2 inhibitor, in adults with moderate to severe plaque psor...
10% Owner
ALUMIS INC ($ALMS)
Transaction Date: Jan 08, 2026
Shares: 294,117
Purchase Price: $17.00
Purchase Value: $4,999,989
📈
P&L: 30.1% ($1,502,938 gain)
📊 Valuation & Analyst Info:
Fair Value: $4.90 (77.8% overvalued vs current price)
Analyst Rating: C+
Avg Price Target: $35.14 (+58.9% vs current)
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 09, 2026
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
GlobeNewsWire • Jan 07, 2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Zacks Investment Research • Jan 07, 2026
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
Seeking Alpha • Jan 07, 2026
Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, wit...
Defense World • Jan 07, 2026
Alumis (NASDAQ: ALMS) used a conference call to highlight positive top-line Phase III results for envudeucitinib, its next-generation oral TYK2 inhibitor, in adults with moderate to severe plaque psor...
Director
AIRWA INC ($CNXA)
Transaction Date: Jan 12, 2026
Shares: 744,496
Purchase Price: $1.41
Purchase Value: $1,049,739
📈
P&L: 6.4% ($67,005 gain)
Director
Sprout Social, Inc ($SPT)
Transaction Date: Jan 09, 2026
Shares: 93,984
Purchase Price: $10.67
Purchase Value: $1,002,621
📉
P&L: 8.2% ($82,518 loss)
📊 Valuation & Analyst Info:
Fair Value: $6.24 (36.3% overvalued vs current price)
Analyst Rating: C
Avg Price Target: $22.00 (+124.7% vs current)
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 12, 2026
CHICAGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today annou...
10% Owner
ASA Gold & Precious Metals Ltd ($ASA)
Transaction Date: Jan 12, 2026
Shares: 9,508
Purchase Price: $64.19
Purchase Value: $610,319
📉
P&L: 0.8% ($4,944 loss)
📊 Valuation & Analyst Info:
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 13, 2026
Please see below information about transactions made under the fourth tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).
Defense World • Jan 11, 2026
ASA Gold and Precious Metals Limited (NYSE: ASA - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 3,598 shares of the firm's stock in a transaction on Wednesday, January 7th...
Defense World • Jan 11, 2026
ASA Gold and Precious Metals Limited (NYSE: ASA - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 3,280 shares of the firm's stock in a transaction on Tuesday, January 6th. ...
📅 Upcoming Earnings: Jan 28, 2026
This newsletter is generated automatically. Please verify all information independently before making investment decisions.